Genmab A/S

Genmab A/S is a biotechnology company based in Denmark that focuses on developing antibody-based products and product candidates for the treatment of cancer and other diseases. The company markets several approved therapies, including EPKINLY and TEPKINLY for adult patients with relapsed or refractory diffuse large B-cell lymphoma, large B-cell lymphoma, and follicular lymphoma; Tivdak for recurrent or metastatic cervical cancer; and DARZALEX/DARZALEX FASPRO for multiple myeloma and light-chain amyloidosis. Additionally, Genmab has a robust pipeline of candidates in various stages of development, such as Epcoritamab for B-cell non-Hodgkin lymphoma, Acasunlimab for non-small cell lung cancer, and Rinatabart Sesutecan for platinum-resistant ovarian cancer. The company also collaborates with other pharmaceutical firms, including AbbVie, Pfizer, and BioNTech, to advance its research and development efforts.

Genmab A/S is listed on the Nasdaq Global Select Market under the ticker symbol GMAB. The company's stock is traded in US dollars (USD), as it is listed on a US exchange. Although Genmab is headquartered in Denmark, its shares are accessible to international investors through the NasdaqGS, which is part of the Nasdaq stock exchange in the United States. This listing provides liquidity and visibility in the global financial markets.

Genmab A/S operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, Genmab focuses on the research, development, and commercialization of innovative antibody-based therapies. Its primary area of focus is oncology, with products and candidates targeting various cancers such as lymphoma, cervical cancer, multiple myeloma, and solid tumors. The company's work also extends to other diseases, including autoimmune conditions and hematological disorders, leveraging its expertise in antibody technology to address significant unmet medical needs.

Genmab A/S is headquartered in Denmark, with its primary operations based in the country. The company serves markets globally, with a strong presence in the United States and Europe. Its approved products, such as EPKINLY, Tivdak, and DARZALEX, are marketed in multiple regions, including the US and Europe. Genmab also collaborates with international partners like AbbVie, Pfizer, and BioNTech to expand the reach of its therapies. The company's pipeline includes candidates targeting a wide range of cancers and other diseases, indicating its commitment to addressing healthcare needs across various geographies.

Genmab's portfolio includes several marketed products and a diverse pipeline. Key marketed therapies are EPKINLY and TEPKINLY for relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma; Tivdak for recurrent or metastatic cervical cancer; DARZALEX/DARZALEX FASPRO for multiple myeloma and light-chain amyloidosis; RYBREVANT for non-small cell lung cancer; TECVAYLI and TALVEY for relapsed or refractory multiple myeloma; Kesimpta for relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. The pipeline features Epcoritamab for B-cell non-Hodgkin lymphoma, Acasunlimab for solid tumors and non-small cell lung cancer, Rinatabart Sesutecan for platinum-resistant ovarian cancer, and several early-stage candidates like GEN1059, GEN1055, and GEN1057 for solid tumors. Additionally, Genmab is developing Amivantamab for head and neck and colorectal cancers, Amlenetug for multiple system atrophy, Inclacumab for sickle cell disease, and Mim8 for hemophilia A.